SURMOUNT trial series (phase 3, obesity) : SURMOUNT1 and related studies evaluated tirzepatide for chronic weight management in people with obesity or overweight with comorbidities these trials reported mean percent weight loss and responder analyses at primary endpoints (often 72 weeks)
Zepbound (tirzepatide), manufactured by Fortune 500 firm Eli Lilly & Co., bested competitor Wegovy (semaglutide), a product of Global 500 company Novo Nordisk, in a recent randomized clinical trial backed by Lilly
Nature 575 , 693698 (2019)
Unlike other face-firming creams, this formula is designed to tackle the unique skincare concerns of rapid GLP-1-induced weight loss think fine lines, decreased density and crepey skin texture
When in doubt: Do not use the medication Contact your pharmacist or healthcare provider How to Check If GLP-1 Is Still Safe Before using your injection, inspect the liquid
Materials Needed Before You Begin Before opening the vial, confirm you have the following on hand: | Material | Specification | |---|---| | Sterile diluent | Sterile water, 0.9% saline, or 0.5 to 1% acetic acid | | Pipettes | Calibrated micropipettes (P200 and P1000) | | Low-protein-binding tubes | 1.5 mL or 0.5 mL microcentrifuge tubes | | Filter (optional) | 0.22 micron PVDF or PES membrane | | Ice | For keeping aliquots cold during handling | | Vortex (do not use for mixing) | Keep nearby but do not vortex peptide | | Analytical balance or CoA | To confirm net peptide content per vial | | Label maker or permanent marker | For aliquot labeling | One step that researchers often overlook is confirming the net peptide content on the Certificate of Analysis (CoA) before calculating how much diluent to add
